CO2022010330A2 - Dosificación de gamma-hidroxibutirato (ghb) - Google Patents

Dosificación de gamma-hidroxibutirato (ghb)

Info

Publication number
CO2022010330A2
CO2022010330A2 CONC2022/0010330A CO2022010330A CO2022010330A2 CO 2022010330 A2 CO2022010330 A2 CO 2022010330A2 CO 2022010330 A CO2022010330 A CO 2022010330A CO 2022010330 A2 CO2022010330 A2 CO 2022010330A2
Authority
CO
Colombia
Prior art keywords
ghb
hydroxybutyrate
gamma
dosage
narcolepsy
Prior art date
Application number
CONC2022/0010330A
Other languages
English (en)
Inventor
Franck Skobieranda
Original Assignee
Jazz Pharmaceuticals Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jazz Pharmaceuticals Ireland Ltd filed Critical Jazz Pharmaceuticals Ireland Ltd
Publication of CO2022010330A2 publication Critical patent/CO2022010330A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)

Abstract

En la presente memoria se proporcionan métodos para administrar formulaciones de GHB para el tratamiento de la narcolepsia y otras afecciones.
CONC2022/0010330A 2019-12-24 2022-07-22 Dosificación de gamma-hidroxibutirato (ghb) CO2022010330A2 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962953288P 2019-12-24 2019-12-24
US202062993372P 2020-03-23 2020-03-23
US202063000547P 2020-03-27 2020-03-27
US202063052676P 2020-07-16 2020-07-16
PCT/US2020/066561 WO2021133778A1 (en) 2019-12-24 2020-12-22 Gamma-hydroxybutyrate (ghb) dosing

Publications (1)

Publication Number Publication Date
CO2022010330A2 true CO2022010330A2 (es) 2022-10-21

Family

ID=74191949

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2022/0010330A CO2022010330A2 (es) 2019-12-24 2022-07-22 Dosificación de gamma-hidroxibutirato (ghb)

Country Status (14)

Country Link
US (2) US20210186907A1 (es)
EP (1) EP4081204A1 (es)
JP (1) JP2023508975A (es)
KR (1) KR20220119429A (es)
CN (1) CN115209885A (es)
AU (1) AU2020414694A1 (es)
BR (1) BR112022012594A2 (es)
CA (1) CA3162974A1 (es)
CL (1) CL2022001743A1 (es)
CO (1) CO2022010330A2 (es)
IL (1) IL294176A (es)
MX (1) MX2022007968A (es)
TW (1) TW202135790A (es)
WO (1) WO2021133778A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011232408B2 (en) 2010-03-24 2015-07-30 Jazz Pharmaceuticals, Inc. Controlled release dosage forms for high dose, water soluble and hygroscopic drug substances
US10398662B1 (en) 2015-02-18 2019-09-03 Jazz Pharma Ireland Limited GHB formulation and method for its manufacture
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US20180263936A1 (en) 2017-03-17 2018-09-20 Jazz Pharmaceuticals Ireland Limited Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
CA3115122A1 (en) 2018-11-19 2020-05-28 Jazz Pharmaceuticals Ireland Limited Alcohol-resistant drug formulations
AU2020231916A1 (en) 2019-03-01 2021-08-05 Flamel Ireland Limited Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1140061T3 (da) 1998-12-23 2003-08-25 Orphan Medical Inc Mikrobiologisk sunde og stabile opløsninger af gamma-hydroxybutyratsalt til behandling af narcolepsi
ES2383673T3 (es) 2000-09-22 2012-06-25 Jpi Commercial, Llc Composiciones de gamma-hidroxibutirato que contienen portadores de hidrato de carbonos
US7610153B2 (en) * 2002-02-13 2009-10-27 Virginia Commonwealth University Multi-drug titration and evaluation
US7668730B2 (en) 2002-12-17 2010-02-23 JPI Commercial, LLC. Sensitive drug distribution system and method
US8771735B2 (en) 2008-11-04 2014-07-08 Jazz Pharmaceuticals, Inc. Immediate release dosage forms of sodium oxybate
US8778398B2 (en) 2008-11-04 2014-07-15 Jazz Pharmaceuticals, Inc. Immediate release formulations and dosage forms of gamma-hydroxybutyrate
US8591922B1 (en) 2012-12-14 2013-11-26 Jazz Pharmacuticals, Inc. Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
US9050302B2 (en) 2013-03-01 2015-06-09 Jazz Pharmaceuticals Ireland Limited Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
US9801852B2 (en) 2013-08-30 2017-10-31 Jazz Pharmaceuticals, Inc. Devices and methods for facilitating and controlling use of a medication
US20180263936A1 (en) * 2017-03-17 2018-09-20 Jazz Pharmaceuticals Ireland Limited Gamma-hydroxybutyrate compositions and their use for the treatment of disorders

Also Published As

Publication number Publication date
MX2022007968A (es) 2022-09-02
BR112022012594A2 (pt) 2022-09-06
CN115209885A (zh) 2022-10-18
US20210186907A1 (en) 2021-06-24
IL294176A (en) 2022-08-01
AU2020414694A1 (en) 2022-08-18
CA3162974A1 (en) 2021-07-01
US20210361601A1 (en) 2021-11-25
JP2023508975A (ja) 2023-03-06
KR20220119429A (ko) 2022-08-29
CL2022001743A1 (es) 2023-02-10
EP4081204A1 (en) 2022-11-02
TW202135790A (zh) 2021-10-01
WO2021133778A1 (en) 2021-07-01

Similar Documents

Publication Publication Date Title
CO2022010330A2 (es) Dosificación de gamma-hidroxibutirato (ghb)
CO2021005987A2 (es) Compuestos de anillo fusionado
CO2020012824A2 (es) Compuestos de 4-aminoisoindolina-1,3-diona sustituidos y su uso para el tratamiento de linfoma
CO2023015484A2 (es) Compuesto, composiciones y métodos para el tratamiento de trastornos
CL2021001395A1 (es) Compuestos derivados de panteteínas cíclicas; composición farmacéutica que los comprende; y su uso para aumentar las concentraciones de acetil-coa, para el tratamiento de cáncer, enfermedad inflamatoria, enfermedad neurodegenerativa, esclerosis múltiple, entre otras enfermedades.
CO2022000481A2 (es) Inhibidores de enzimas
EA202191519A1 (ru) Модуляторы trex1
CO2022001210A2 (es) Conjugados de il-2 y métodos de uso para tratar enfermedades autoinmunes
CL2021001593A1 (es) Tubulisinas y conjugados de proteína-tubulisina
CL2020002624A1 (es) Formulaciones de inmunoconjugado anti-cd79b estables.
DOP2020000100A (es) Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3
ECSP23057264A (es) Inhibidores de cdk2 y métodos de uso de los mismos
CL2019002583A1 (es) Inhibidores duales de magl y faah.
ECSP22044525A (es) Terapia de combinaci?n que comprende un inhibidor de alk2 y un inhibidor de jak2
CL2022000967A1 (es) Composiciones y métodos para el tratamiento de enfermedades hepáticas
CO2022000270A2 (es) Inhibidores de enzimas
CL2020001062A1 (es) Sulfonas y sulfóxidos bicíclicos y métodos de uso de los mismos.
CL2021000924A1 (es) Uso de reboxetina para el tratamiento de narcolepsia
CO2022007814A2 (es) Ligandos de la pseudoquinasa tyk2
CL2021002318A1 (es) Métodos de tratamiento de amiloidosis al
CO2022014499A2 (es) Moduladores de nlrp3
CL2022002589A1 (es) Tratamiento de trastornos respiratorios
MX2020004513A (es) Cocristales, composiciones farmacéuticas de los mismos y métodos de tratamiento que los implican.
CL2022003206A1 (es) Compuestos derivados de quinolona y su uso para el tratamiento del cáncer (div. sol. 202102501)
CL2021003442A1 (es) Composición farmacéutica que comprende idelalisib y defactinib; y métodos para el tratamiento de cáncer.